Document is current
Any future updates will be listed below
-
Authors
Lee, Eunhyeong
Lee, Eun-Ah
Kong, Eunji
Chon, Haemin
Llaiqui-Condori, Melissa
Park, Cheon Ho
Park, Beom Yong
Kang, Nu Ri
Yoo, Jin-San
Lee, Hyun-Soo
Kim, Hyung-Seok
Park, Sung-Hong https://orcid.org/0000-0002-1731-0668
Choi, Seung-Won https://orcid.org/0000-0003-1203-6126
Vestweber, Dietmar
Lee, Jeong Ho https://orcid.org/0000-0002-2299-630X
Kim, Pilhan https://orcid.org/0000-0001-8388-1840
Lee, Weon Sup
Kim, Injune https://orcid.org/0000-0001-9244-815X
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2018R1A2A1A05022672)
National Research Foundation of Korea (2021R1A4A1031198)
National Research Foundation of Korea (2021R1A2C3006538)
National Research Foundation of Korea (2019R1A2C1089108)
National Research Foundation of Korea (2020R1A4A1018714)
KAIST (N11180156)
KAIST (N11180156)
KAIST (N11220110)
- License Information
-
More Information
Article History
Received: 28 July 2022
Revised: 5 December 2022
Accepted: 8 December 2022
First Online: 24 February 2023
Competing interests
: E.-A.L., C.H.P., B.Y.P., N.K., J.-S.Y. and W.S.L. are coinventors of the 4E2 antibody and stockholders of PharmAbcine Inc., which has the right to use the 4E2 antibody. P.K. is a founder, stockholder, and chief executive officer of IVIM Technology, Inc., which provides intravital confocal and two-photon microscopes. J.H.L. is a co-founder and the chief technology officer of SoVarGen, Inc., which has the right to use the hybrid plasmid for GBM induction. The remaining authors declare no potential conflicts of interest.
